Cargando…
Direct oral anticoagulation and severe obesity – One size fits all?
Oral anticoagulation is obligatory in patients with atrial fibrillation (AF) to prevent thromboembolic stroke. Direct direct oral anticoagulants (DOAC) exhibit improved safety over Vitamin K antagonists, but any interference in haemostasis can impact on bleeding. Optimal anticoagulation remains chal...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654775/ https://www.ncbi.nlm.nih.gov/pubmed/34934804 http://dx.doi.org/10.1016/j.ijcha.2021.100923 |
_version_ | 1784611936000802816 |
---|---|
author | Fender, Anke C. Gawalko, Monika Dobrev, Dobromir |
author_facet | Fender, Anke C. Gawalko, Monika Dobrev, Dobromir |
author_sort | Fender, Anke C. |
collection | PubMed |
description | Oral anticoagulation is obligatory in patients with atrial fibrillation (AF) to prevent thromboembolic stroke. Direct direct oral anticoagulants (DOAC) exhibit improved safety over Vitamin K antagonists, but any interference in haemostasis can impact on bleeding. Optimal anticoagulation remains challenging particularly in patients with co-morbidities. International Society of Thrombosis and Haemostasis (ISTH) guidelines recommend avoiding DOAC in patients with severe obesity, and systematic data on individual DOAC drug concentrations, clinical efficacy and safety in relation to body weight are lacking. A new study now provides reassurance that DOAC are safe and effective in a real-world cohort of morbidly obese patients, going some way to fill the knowledge gap pertaining to optimal management of concomitant obesity and AF. |
format | Online Article Text |
id | pubmed-8654775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86547752021-12-20 Direct oral anticoagulation and severe obesity – One size fits all? Fender, Anke C. Gawalko, Monika Dobrev, Dobromir Int J Cardiol Heart Vasc Editorial Oral anticoagulation is obligatory in patients with atrial fibrillation (AF) to prevent thromboembolic stroke. Direct direct oral anticoagulants (DOAC) exhibit improved safety over Vitamin K antagonists, but any interference in haemostasis can impact on bleeding. Optimal anticoagulation remains challenging particularly in patients with co-morbidities. International Society of Thrombosis and Haemostasis (ISTH) guidelines recommend avoiding DOAC in patients with severe obesity, and systematic data on individual DOAC drug concentrations, clinical efficacy and safety in relation to body weight are lacking. A new study now provides reassurance that DOAC are safe and effective in a real-world cohort of morbidly obese patients, going some way to fill the knowledge gap pertaining to optimal management of concomitant obesity and AF. Elsevier 2021-12-06 /pmc/articles/PMC8654775/ /pubmed/34934804 http://dx.doi.org/10.1016/j.ijcha.2021.100923 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Editorial Fender, Anke C. Gawalko, Monika Dobrev, Dobromir Direct oral anticoagulation and severe obesity – One size fits all? |
title | Direct oral anticoagulation and severe obesity – One size fits all? |
title_full | Direct oral anticoagulation and severe obesity – One size fits all? |
title_fullStr | Direct oral anticoagulation and severe obesity – One size fits all? |
title_full_unstemmed | Direct oral anticoagulation and severe obesity – One size fits all? |
title_short | Direct oral anticoagulation and severe obesity – One size fits all? |
title_sort | direct oral anticoagulation and severe obesity – one size fits all? |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654775/ https://www.ncbi.nlm.nih.gov/pubmed/34934804 http://dx.doi.org/10.1016/j.ijcha.2021.100923 |
work_keys_str_mv | AT fenderankec directoralanticoagulationandsevereobesityonesizefitsall AT gawalkomonika directoralanticoagulationandsevereobesityonesizefitsall AT dobrevdobromir directoralanticoagulationandsevereobesityonesizefitsall |